Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATA

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the p

Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perf

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall S

Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript

Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday mid

Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth f

Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst c

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a

Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report)'s share price gapped down

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and

Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob

BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg

On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykt

UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers

Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre

JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announce

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and

Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get th

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday.

US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.

Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg

Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with rel

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with re

BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Lege

UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price

Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad

Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety,

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T

Legend Biotech's experimental therapy showed early signs that its approach of generating disease-fig

BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Lege

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors am

BRIDGEWATER, N.J., June 01, 2026 (GLOBE NEWSWIRE) --  Legend Biotech Corporation (NASDAQ: LEGN) (Leg

Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript

Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physi

SOMERSET, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend B

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a

Legend Biotech develops cell therapies for cancer, with a pipeline spanning hematologic malignancies

Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing e

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and raises the p